Response to anti-PD-1 immunotherapy in lung cancer could be determined by eNose

A recent study published in Annals of Oncology describes the development of an electronic nose (eNose) that can determine the response of a lung cancer patient to anti-PD-1 immunotherapy. Results report an 85% degree of accuracy, which is more so than current immunohistochemistry methods.A research group, led by a team from Radboud University Medical Centre (Netherlands), has recently published a report in Annals of Oncology that describes a novel method of determining the response to anti-PD-1 immunotherapy in non-small cell lung cancer (NSCLC) patients. The eNose is used to ‘smell’ the breath of patients and identify the response to treatments...